NCT06323382
- Conditions
- Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
- Locations
-
- Chinese PLA hospital Beijing, Beijing Municipality, China
Clinical trial condition
Anti-PD1/PDL1 Antibody
Explore clinical trials studying Anti-PD1/PDL1 Antibody. Study availability and eligibility vary by location and protocol.
1 public trial
1 recruiting study